Development and Characterization of Methotrexate-Loaded Nanomicelles for Ocular Drug Delivery
International Journal of Drug Delivery Technology · 25.12.2025 · 15 (04)
DOI: 10.25258/ijddt.15.4.40 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 25.12.2025. Verfasst von Mr. Akashdeep Udmale und 1 weiteren Autor:innen.
Abstract (Originalsprache)
This research was focused on the formulation and characterization of nanomicelles loaded with methotrexate (MTX) to improve the drug's solubility and assess its viability for ocular applications. The synthesis of the nanomicelles was achieved through a co-solvent evaporation technique, which involved using Soluplus® as the polymer and Poloxamer 407 as the surfactant. For the purpose of optimizing the formulation, a Box-Behnken design was utilized. The prepared nanomicelles underwent comprehensive evaluation for parameters such as particle size, polydispersity index (PDI), drug content, and physical stability. Further in-depth characterization involved Fourier-Transform Infrared (FTIR) spectroscopy, Differential Scanning Calorimetry (DSC), and Transmission Electron Microscopy (TEM). Preformulation studies established the λmax of MTX at 304 nm. Among various solvents tested, methanol was determined to be the most effective, yielding a solubility of 24.27 μg/mL. Compatibility assessments confirmed no significant chemical interactions between MTX and the selected excipients. Out of fourteen formulations prepared, F10 was singled out as the optimized batch. It demonstrated the highest drug content at 99.88% and the smallest particle size of 32.16 nm, although it presented a moderate PDI of 0.470. Analysis of variance (ANOVA) validated the predictive capability of the quadratic model for drug content. The in vitro drug release study of F10 showed a cumulative release of 97.2% over a 12-hour period, adhering to a zero-order kinetic model (R²=0.9679), which suggests a sustained and controlled release mechanism. Stability assessments conducted over six months verified the formulation's integrity. These results indicate that the optimized MTX-loaded nanomicelle formulation (F10) represents a highly promising candidate for the creation of advanced ocular drug delivery systems.
Zitieren
APA
Udmale, M. A., & Patel, D. V. (2025). Development and Characterization of Methotrexate-Loaded Nanomicelles for Ocular Drug Delivery. International Journal of Drug Delivery Technology, 15(04). https://doi.org/10.25258/ijddt.15.4.40
Vancouver
Udmale MA, Patel DV. Development and Characterization of Methotrexate-Loaded Nanomicelles for Ocular Drug Delivery. International Journal of Drug Delivery Technology. 2025;15(04). doi:10.25258/ijddt.15.4.40
BibTeX
@article{Udmale2025,
author = {Udmale, Mr. Akashdeep and Patel, Dr. VipulKumar},
title = {Development and Characterization of Methotrexate-Loaded Nanomicelles for Ocular Drug Delivery},
journal = {International Journal of Drug Delivery Technology},
year = {2025},
volume = {15},
number = {04},
doi = {10.25258/ijddt.15.4.40}
}
EUVIMED